Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 9, 2013, Pages 1545-1554

  Pok, Sharon ^a   Wen, Victoria ^c   Shackel, Nicholas ^c   Alsop, Amber ^b   Pyakurel, Pawan ^a   Fahrer, Aude ^b   Farrell, Geoffrey C ^a   Teoh, Narci C ^a  

^a The Australian National University   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

Apoptosis; Diethylnitrosamine; Hepatocellular carcinoma; miR 34; P21

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLINE; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE P1; MICRORNA 34A; PROTEIN BCL XL; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

APOPTOSIS; DIETHYLNITROSAMINE; HEPATOCELLULAR CARCINOMA; MIR-34; P21;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; DIETHYLNITROSAMINE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84897584178     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12216     Document Type: Article

References (27)

1. El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365: 1118-1127.
2. Buendia MA. Genetics of hepatocellular carcinoma. Semin. Cancer Biol. 2000; 10: 185-200.
3. Raidl M, Pirker C, Schulte-Hermann R etal. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J. Hepatol. 2004; 40: 660-668.
4. Teoh NC, Dan YY, Swisshelm K etal. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008; 47: 2078-2088.
5. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S. Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996; 111: 455-461.
6. Nishimura T, Nishida N, Komeda T, Fukuda Y, Nakao K. Genotype stability and clonal evolution of hepatocellular carcinoma assessed by autopsy-based genome-wide microsatellite analysis. Cancer Genet. Cytogenet. 2005; 161: 164-169.
7. Meyer M, Wiedorn KH, Hofschneider PH, Koshy R, Caselmann WH. A chromosome 17:7 translocation is associated with A hepatitis B virus DNA integration in human hepatocellular carcinoma DNA. Hepatology 1992; 15: 665-671.
8. Teoh NC, Pyakurel P, Dan YY etal. Induction of P53 renders ATM-deficient mice refractory to hepatocarcinogenesis. Gastroenterology 2010; 138: 1155-1165.
9. Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW, Albrecht JH. Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res. 2001; 61: 8564-8568.
10. Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005; 24: 2776-2786.
11. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999; 401: 297-300.
12. Ohashi R, Gao C, Miyazaki M etal. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001; 21: 657-662.
13. Dutta U, Kench J, Byth K etal. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum. Pathol. 1998; 29: 1279-1284.
14. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009; 10: 704-714.
15. He L, He X, Lim L etal. A microRNA component of the P53 tumour suppressor network. Nature 2007; 447: 1130-1134.
16. Koff A, Giordano A, Desai D etal. Formation and activation of A cyclin E-Cdk2 complex during the G1 phase of the human cell cycle. Science 1992; 257: 1689-1694.
17. Vogelstein B, Lane D, Levine A. Surfing the P53 network. Nature 2000; 408: 307-310.
18. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-Cdk2 activation through P21 redistribution. Mol. Cell. Biol. 1997; 17: 4059-4069.
19. Hoeijmakers JH. DNA damage, aging, and cancer. N. Engl. J. Med. 2009; 361: 1475-1485.
20. Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing? J. Gastroenterol. Hepatol. 2009; 24: 1817-1825.
21. Lee JS, Grisham JW, Thorgeirsson SS. Comparative functional genomics for identifying models of human cancer. Carcinogenesis 2005; 26: 1013-1020.
22. Lee JS, Thorgeirsson SS. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004; 127: S51-55.
23. Ji J, Shi J, Budhu A etal. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 2009; 361: 1437-1447.
24. Chang TC, Wentzel EA, Kent OA etal. Transactivation of Mir-34a by P53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007; 26: 745-752.
25. Calin GA, Sevignani C, Dumitru CD etal. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 2999-3004.
26. Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003; 22: 6609-6620.
27. Bettayeb K, Oumata N, Echalier A etal. Cr8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008; 27: 5797-5807.